List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4130247/publications.pdf Version: 2024-02-01



ANNA EDDEL

#	Article	IF	CITATIONS
1	Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature, 1985, 317, 264-267.	27.8	251
2	C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury. Journal of Immunology, 2004, 173, 747-754.	0.8	155
3	Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. Neurobiology of Disease, 2004, 17, 155-162.	4.4	140
4	The role of C3 in the immune response. Trends in Immunology, 1991, 12, 332-337.	7.5	123
5	Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. Journal of Neuroimmunology, 2004, 155, 55-63.	2.3	119
6	The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes. Immunology Letters, 2017, 189, 64-72.	2.5	99
7	Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3,) Tj ETQq1 1 0	.784314 ı 0.8	gBT/Overlo
8	The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes. European Journal of Immunology, 1985, 15, 184-188.	2.9	85
9	Complement Receptor Type 1 (CD35) Mediates Inhibitory Signals in Human B Lymphocytes. Journal of Immunology, 2002, 168, 2782-2788.	0.8	85
10	Rhinophototherapy: A new therapeutic tool for the management of allergic rhinitis. Journal of Allergy and Clinical Immunology, 2005, 115, 541-547.	2.9	76
11	Complement protein C1q induces maturation of human dendritic cells. Molecular Immunology, 2007, 44, 3389-3397.	2.2	76
12	Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. Molecular Immunology, 2009, 46, 2767-2773.	2.2	76
13	CD11c/CD18 Dominates Adhesion of Human Monocytes, Macrophages and Dendritic Cells over CD11b/CD18. PLoS ONE, 2016, 11, e0163120.	2.5	72
14	Expression and role of Fc- and complement-receptors on human dendritic cells. Immunology Letters, 2006, 104, 46-52.	2.5	65
15	The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathologica, 2007, 113, 153-161.	7.7	65
16	Neonatal FcR Overexpression Boosts Humoral Immune Response in Transgenic Mice. Journal of Immunology, 2011, 186, 959-968.	0.8	65
17	Non-identical twins: Different faces of CR3 and CR4 in myeloid and lymphoid cells of mice and men. Seminars in Cell and Developmental Biology, 2019, 85, 110-121.	5.0	64
18	Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Molecular Immunology, 2004, 40, 1213-1221.	2.2	57

#	Article	IF	CITATIONS
19	Complement research: biosynthesis, genetics, immunoregulatory role and clinical studies. Trends in Immunology, 1992, 13, A10-A12.	7.5	56
20	Cross-Linking of CD32 Induces Maturation of Human Monocyte-Derived Dendritic Cells Via NF-κB Signaling Pathway. Journal of Immunology, 2003, 170, 3963-3970.	0.8	55
21	FHR-4A: a new factor H-related protein is encoded by the human FHR-4 gene. European Journal of Human Genetics, 2005, 13, 321-329.	2.8	45
22	Immune-complex-induced transglut aminase activation: Its role in the Fc-receptor-mediated transmembrane effect on peritoneal macrophages. Molecular Immunology, 1981, 18, 633-638.	2.2	44
23	B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacityâ~†. Molecular Immunology, 2008, 45, 2343-2351.	2.2	44
24	Reversible biotinylation of C1q with a cleavable biotinyl derivative. Journal of Immunological Methods, 1988, 110, 251-260.	1.4	43
25	Phosphorylation adjacent to the nuclear localization signal of human dUTPase abolishes nuclear import: structural and mechanistic insights. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 2495-2505.	2.5	42
26	Regulation of mast cell activation by complement-derived peptides. Immunology Letters, 2004, 92, 39-42.	2.5	41
27	Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. Aids, 1997, 11, 949-958.	2.2	39
28	Developmental Regulation of dUTPase in Drosophila melanogaster. Journal of Biological Chemistry, 2004, 279, 22362-22370.	3.4	38
29	Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. International Immunology, 2013, 25, 25-33.	4.0	35
30	Interaction of TPPP/p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. FEBS Letters, 2006, 580, 5807-5814.	2.8	34
31	Physiological up-regulation of inhibitory receptors FcÂRII and CR1 on memory B cells is lacking in SLE patients. International Immunology, 2008, 20, 185-192.	4.0	34
32	The versatile functions of complement C3â€derived ligands. Immunological Reviews, 2016, 274, 127-140.	6.0	34
33	The Clq receptor. Molecular Immunology, 1988, 25, 1067-1073.	2.2	33
34	Role of C3b receptors in the enhancement of interleukin-2-dependent T-cell proliferation. Molecular Immunology, 1984, 21, 1215-1221.	2.2	32
35	H1 histamine receptor antagonist inhibits constitutive growth of Jurkat T cells and antigen-specific proliferation of ovalbumin-specific murine T cells. Seminars in Cancer Biology, 2000, 10, 41-45.	9.6	32
36	CR3 is the dominant phagocytotic complement receptor on human dendritic cells. Immunobiology, 2013, 218, 652-663.	1.9	32

#	Article	IF	CITATIONS
37	Secreted aspartic protease 2 of Candida albicans inactivates factor H and the macrophage factor H-receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18). Immunology Letters, 2015, 168, 13-21.	2.5	32
38	Single Cell Adhesion Assay Using Computer Controlled Micropipette. PLoS ONE, 2014, 9, e111450.	2.5	30
39	In-situ and label-free optical monitoring of the adhesion and spreading of primary monocytes isolated from human blood: Dependence on serum concentration levels. Biosensors and Bioelectronics, 2014, 54, 339-344.	10.1	30
40	Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Immunopharmacology, 1999, 42, 159-165.	2.0	29
41	Bone marrowâ€derived mast cell differentiation is strongly reduced in histidine decarboxylase knockout, histamineâ€free mice. International Immunology, 2002, 14, 381-387.	4.0	29
42	An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes. Immunology Letters, 2008, 116, 168-173.	2.5	28
43	Antigen microarrays: descriptive chemistry or functional immunomics?. Trends in Immunology, 2010, 31, 133-137.	6.8	28
44	Regulation of B-Cell Activation by Complement Receptors CD21 and CD35. Current Pharmaceutical Design, 2003, 9, 1849-1860.	1.9	28
45	Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages. European Journal of Immunology, 2000, 30, 1706-1713.	2.9	27
46	Immunomodulatory functions of murine CR1/2. Immunopharmacology, 2000, 49, 117-124.	2.0	27
47	Modeling the presentation of C3d-coated antigen by B lymphocytes: enhancement by CR1/2–BCR co-ligation is selective for the co-ligating antigen. International Immunology, 2002, 14, 241-247.	4.0	26
48	Syk is indispensable for CpG-induced activation and differentiation of human B cells. Cellular and Molecular Life Sciences, 2015, 72, 2223-2236.	5.4	26
49	Label-free optical biosensor for on-line monitoring the integrated response of human B cells upon the engagement of stimulatory and inhibitory immune receptors. Sensors and Actuators B: Chemical, 2017, 240, 528-535.	7.8	23
50	New aspects in the regulation of human B cell functions by complement receptors CR1, CR2, CR3 and CR4. Immunology Letters, 2021, 237, 42-57.	2.5	23
51	A novel fruitfly protein under developmental control degrades uracil-DNA. Biochemical and Biophysical Research Communications, 2007, 355, 643-648.	2.1	22
52	Complement receptor type 1 (CR1/CD35) expressed on activated human CD4+ T cells contributes to generation of regulatory T cells. Immunology Letters, 2015, 164, 117-124.	2.5	22
53	Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1023-1031.	3.3	22
54	Complement peptide C3a inhibits IgEmediated triggering of rat mucosal mast cells. International Immunology, 1995, 7, 1433-1439.	4.0	21

#	Article	IF	CITATIONS
55	dUTPase and Nucleocapsid Polypeptides of the Mason-Pfizer Monkey Virus Form a Fusion Protein in the Virion with Homotrimeric Organization and Low Catalytic Efficiency. Journal of Biological Chemistry, 2003, 278, 38803-38812.	3.4	21
56	Cellular Response to Efficient dUTPase RNAi Silencing in Stable HeLa Cell Lines Perturbs Expression Levels of Genes Involved in Thymidylate Metabolism. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 369-390.	1.1	21
57	The differential role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in the adherence, migration and podosome formation of human macrophages and dendritic cells under inflammatory conditions. PLoS ONE, 2020, 15, e0232432.	2.5	21
58	Revisiting the Coreceptor Function of Complement Receptor Type 2 (CR2, CD21); Coengagement With the B-Cell Receptor Inhibits the Activation, Proliferation, and Antibody Production of Human B Cells. Frontiers in Immunology, 2021, 12, 620427.	4.8	21
59	Macrophage-Bound C3 Fragments as Adhesion Molecules Modulate Presentation of Exogenous Antigens. Immunobiology, 1992, 185, 314-326.	1.9	20
60	The β Subunit of the Type I Fcε Receptor Is a Target for Peptides Inhibiting IgE-Mediated Secretory Response of Mast Cells. Journal of Immunology, 2005, 175, 2801-2806.	0.8	20
61	Appearance of acceptor-bound C3b on HLA-DR positive macrophages and on stimulated U937 cells; Inhibition of Fcî ³ -receptors by the covalently fixed C3 fragments. Molecular Immunology, 1988, 25, 295-303.	2.2	19
62	Characterization of the interleukin 5-reactive splenic B cell population. European Journal of Immunology, 1990, 20, 1949-1956.	2.9	19
63	The role of CR2 in autoimmunity. Autoimmunity, 2006, 39, 357-366.	2.6	19
64	On-chip Complement Activation Adds an Extra Dimension to Antigen Microarrays. Molecular and Cellular Proteomics, 2007, 6, 133-140.	3.8	19
65	Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies. MAbs, 2011, 3, 431-439.	5.2	19
66	Utilization of complement receptors in immune cell–microbe interaction. FEBS Letters, 2020, 594, 2695-2713.	2.8	19
67	Functionally active C1 on the surface of human peripheral lymphocytes: Its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes. Clinical Immunology and Immunopathology, 1976, 5, 377-387.	2.0	18
68	Elimination of autoreactive B cells in humanized SCID mouse model of SLE. European Journal of Immunology, 2011, 41, 3301-3311.	2.9	18
69	Complement peptides and mast cell triggering. Immunology Letters, 1996, 54, 109-112.	2.5	17
70	Novel roles for murine complement receptors type 1 and 2. Immunology Letters, 2008, 116, 156-162.	2.5	17
71	A novel, complement-mediated way to enhance the interplay between macrophages, dendritic cells and T lymphocytes. Molecular Immunology, 2009, 47, 438-448.	2.2	17
72	Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr mice. Rheumatology, 2010, 49, 2273-2280.	1.9	17

#	Article	IF	CITATIONS
73	The Fc receptor model of membrane cytoplasmic signalling. Molecular Immunology, 1982, 19, 1223-1228.	2.2	16
74	Cell cycle control of activated, synchronized murine B lymphocytes—roles of macrophages and complement C3. Molecular Immunology, 1986, 23, 1173-1176.	2.2	15
75	Inhibition of IgE-mediated triggering of mast cells by complement-derived peptides interacting with the FcεRI. Immunology Letters, 1999, 68, 79-82.	2.5	15
76	Transgenic expression of bovine neonatal Fc receptor in mice boosts immune response and improves hybridoma production efficiency without any sign of autoimmunity. Immunology Letters, 2011, 137, 62-69.	2.5	15
77	Human T cell derived, cell-bound complement iC3b is integrally involved in T cell activation. Immunology Letters, 2012, 143, 131-136.	2.5	15
78	Adhesion kinetics of human primary monocytes, dendritic cells, and macrophages: Dynamic cell adhesion measurements with a label-free optical biosensor and their comparison with end-point assays. Biointerphases, 2016, 11, 031001.	1.6	15
79	Detection of Complement Activation on Antigen Microarrays Generates Functional Antibody Profiles and Helps Characterization of Disease-Associated Changes of the Antibody Repertoire. Journal of Immunology, 2008, 181, 8162-8169.	0.8	14
80	Activated Human Memory B Lymphocytes Use CR4 (CD11c/CD18) for Adhesion, Migration, and Proliferation. Frontiers in Immunology, 2020, 11, 565458.	4.8	14
81	Twoâ€dimensional immune profiles improve antigen microarrayâ€based characterization of humoral immunity. Proteomics, 2008, 8, 2840-2848.	2.2	13
82	Automated single cell sorting and deposition in submicroliter drops. Applied Physics Letters, 2014, 105, .	3.3	13
83	Complement Receptor Type 1 Suppresses Human B Cell Functions in SLE Patients. Journal of Immunology Research, 2016, 2016, 1-10.	2.2	13
84	Studies on the mechanism of the complement-mediated inhibition of the Fc and C3 receptors of B lymphocytes. Clinical Immunology and Immunopathology, 1977, 8, 367-376.	2.0	12
85	Mucosal type mast cells express complement receptor type 2 (CD21). Immunology Letters, 2002, 82, 29-34.	2.5	12
86	Transient decomplementation of mice delays onset of experimental autoimmune encephalomyelitis and impairs MOG-specific T cell response and autoantibody production. Molecular Immunology, 2009, 47, 57-63.	2.2	12
87	Functional studies of chronic lymphocytic leukemia B cells expressing β 2 -integrin type complement receptors CR3 and CR4. Immunology Letters, 2017, 189, 73-81.	2.5	12
88	Set a thief to catch a thief: Self-reactive innate lymphocytes and self tolerance. Autoimmunity Reviews, 2008, 7, 278-283.	5.8	11
89	Complement Factor H-Related Proteins FHR1 and FHR5 Interact With Extracellular Matrix Ligands, Reduce Factor H Regulatory Activity and Enhance Complement Activation. Frontiers in Immunology, 2022, 13, 845953.	4.8	11
90	A novel, complement factor H-related regulatory protein expressed on the surface of human B cell lines. European Journal of Immunology, 1994, 24, 867-872.	2.9	10

#	Article	IF	CITATIONS
91	Novel roles for murine complement receptors type 1 and 2. Immunology Letters, 2008, 116, 163-167.	2.5	10
92	Complement Receptor Type 1 (CR1, CD35), the Inhibitor of BCR-Mediated Human B Cell Activation, Differentially Regulates TLR7, and TLR9 Induced Responses. Frontiers in Immunology, 2019, 10, 1493.	4.8	10
93	Regulation of B cell functions by Toll-like receptors and complement. Immunology Letters, 2016, 178, 37-44.	2.5	9
94	Interaction between C3 and IL-2; inhibition of C3b binding to CR1 by IL-2. Immunology Letters, 1989, 21, 131-137.	2.5	8
95	Altered Expression of Fc and Complement Receptors on B Cells in Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2007, 1108, 183-192.	3.8	8
96	C3a-derived peptide binds to the type I FcÂR and inhibits proximal-coupling signal processes and cytokine secretion by mast cells. International Immunology, 2008, 20, 1239-1245.	4.0	8
97	Impact of molecular mimicry on the clinical course and outcome of sepsis syndrome. Molecular Immunology, 2011, 49, 512-517.	2.2	8
98	Modulation of immune response by combined targeting of complement receptors and low-affinity Fcl ³ receptors. Immunology Letters, 2010, 130, 66-73.	2.5	7
99	Characterization of factors influencing on-chip complement activation to optimize parallel measurement of antibody and complement proteins on antigen microarrays. Journal of Immunological Methods, 2012, 375, 75-83.	1.4	7
100	Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. Frontiers in Immunology, 2021, 12, 660382.	4.8	7
101	Label-free real-time monitoring of the BCR-triggered activation of primary human B cells modulated by the simultaneous engagement of inhibitory receptors. Biosensors and Bioelectronics, 2021, 191, 113469.	10.1	7
102	Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro. PLoS ONE, 2015, 10, e0124234.	2.5	7
103	C3b Acceptors on macrophages: Inhibition of Fcγ-receptor-mediated phagocytosis by acceptor-bound C3b. Immunology Letters, 1983, 6, 287-291.	2.5	6
104	Modulation of Fc receptor mediated functions by split products of C3. Molecular Immunology, 1984, 21, 1205-1210.	2.2	6
105	Association of RNA with the uracilâ€ÐNAâ€degrading factor has major conformational effects and is potentially involved in protein folding. FEBS Journal, 2011, 278, 295-315.	4.7	6
106	Coadministration of antigen-conjugated and free CpG: Effects of in vitro and in vivo interactions in a murine model. Immunology Letters, 2014, 160, 178-185.	2.5	6
107	Murine CR1/2 Targeted Antigenized Single-Chain Antibody Fragments Induce Transient Low Affinity Antibodies and Negatively Influence an Ongoing Immune Response. , 2007, 598, 214-225.		6
108	Complement-dependent inhibition of Fc receptors on human peripheral blood mononuclear cells: inhibition of the binding of aggregated IgG, soluble and particulate immune complexes. Immunology Letters, 1980, 1, 223-226.	2.5	5

#	Article	lF	CITATIONS
109	Cold target competition analysis of the classical activation pathway of complement-mediated cytotoxicity: A non-interaction model for competing lysis. Molecular Immunology, 1992, 29, 1347-1355.	2.2	5
110	EFIS: Driving women's representation in immunology in Europe. European Journal of Immunology, 2014, 44, 615-616.	2.9	5
111	Natural Compounds as Target Biomolecules in Cellular Adhesion and Migration: From Biomolecular Stimulation to Label-Free Discovery and Bioactivity-Based Isolation. Biomedicines, 2021, 9, 1781.	3.2	5
112	Functional cooperation of C3b-acceptors, FcÎ ³ -receptors and cell-surface proteases on macrophages. Immunology Letters, 1985, 11, 141-146.	2.5	4
113	HIV-1 induces human monocyte-derived macrophages to produce C3 and to fix C3 on their surface. Journal of Leukocyte Biology, 1998, 63, 463-468.	3.3	4
114	Bacterially expressed human FcγRIIb is soluble and functionally active after in vitro refolding. Immunology Letters, 2000, 75, 33-40.	2.5	4
115	Mathematical analysis of clinical data reveals a homunculus of bacterial mimotopes protecting from autoimmunity via oral tolerance in human. Molecular Immunology, 2009, 46, 1673-1678.	2.2	4
116	Modulation of the humoral immune response by targeting CD40 and FcγRII/III; delivery of soluble but not particulate antigen to CD40 enhances antibody responses with a Th1 bias. Molecular Immunology, 2011, 49, 155-162.	2.2	4
117	Generation of Gene-Engineered Chimeric DNA Molecules for Specific Therapy of Autoimmune Diseases. Human Gene Therapy Methods, 2012, 23, 357-365.	2.1	4
118	Differential effect of low molecular weight alcohols on the Con A stimulation of mouse spleen cells. Immunology Letters, 1982, 4, 305-309.	2.5	3
119	Effector or target cell selection mediated by C3 bridges. Immunology Letters, 1987, 14, 243-248.	2.5	3
120	Mucosal Immunity and the Intestinal Microbiome in the Development of Critical Illness. ISRN Immunology, 2011, 2011, 1-12.	0.7	3
121	Effect of binding of C3 and its fragments on the plasma membrane fluidity of lymphocytes. Immunology Letters, 1980, 2, 115-118.	2.5	2
122	Characterization of factor H-related cell membrane molecules expressed by human B lymphocytes and neutrophil granulocytes. Immunology Letters, 2001, 77, 55-62.	2.5	2
123	Targeting with scFv: immune modulation by complement receptor specific constructs. Journal of Molecular Recognition, 2003, 16, 318-323.	2.1	2
124	Non-CpG Oligonucleotides Exert Adjuvant Effects by Enhancing Cognate B Cell-T Cell Interactions, Leading to B Cell Activation, Differentiation, and Isotype Switching. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	2
125	lgG-Fc receptors differ in sensitivity to primary amines. Immunology Letters, 1983, 6, 265-269.	2.5	1
126	Novel regulators of the humoral immune response. Trends in Immunology, 1992, 13, A4-A6.	7.5	1

#	Article	IF	CITATIONS
127	The Role of the Complement System in the Pathogenesis of Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. , 2006, 586, 177-188.		1
128	Introduction. Immunology Letters, 2010, 130, 1.	2.5	1
129	BCR activated CLL B cells use both CR3 (CD11b/CD18) and CR4 (CD11c/CD18) for adhesion while CR4 has a dominant role in migration towards SDF-1. PLoS ONE, 2021, 16, e0254853.	2.5	1
130	Interference of β2-microglobulin specific autoantibodies with EA-binding of human peripheral lymphocytes; Inhibition of B-cell and enhancement of T-lymphocyte Fc-receptors. Immunology Letters, 1981, 3, 215-220.	2.5	0
131	Regulation of B-cell activation by complement receptors CR1 (CD35) and CR2 (CD21)—possible involvement in the pathogenesis of autoimmune diseases. Autoimmunity Reviews, 2004, 3, 624-625.	5.8	0
132	Establishment of the "EFIS-Lecture Award― Immunology Letters, 2005, 100, 5.	2.5	0
133	News and EFIS - Eur. J. Immunol. 6/2008. European Journal of Immunology, 2008, 38, 1476-1478.	2.9	0
134	Introduction. Immunology Letters, 2008, 116, 103.	2.5	0
135	Robert B. Sim—Tribute. Viruses, 2021, 13, 1681.	3.3	0